FRATTAROLI JOSEPH
Known title: Chief Financial OfficerCIK: 0001272668
FRATTAROLI JOSEPH's purchase track record
FRATTAROLI JOSEPH has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/19/2022 | IKT | $3K | +27.3% | +10.3% | +1.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IKT | ▲ Buy | Open Market | 3,948 | $3K | 5/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Inhibikase Announces Nasdaq Inducement Grants
Inhibikase Therapeutics disclosed that it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). This type of grant is typically used to attract or retain new employees without requiring a shareholder vote. The company's stock is currently trading near its 52-week low, with an average analyst target of $6.00.
Inhibikase Announces Nasdaq Inducement Grants. Inhibikase Therapeutics disclosed that it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). This type of grant is typically used to attract or retain new employees without requiring a shareholder vote. The company's stock is currently trading near its 52-week low, with an average analyst target of $6.00.